Feb 11, 2019
1:15
For every 15 shares held, investors received 1.
The split itself did not change the total investment value.
Celldex Therapeutics, Inc. (GETTEX:TCE2) operates in the Biotechnology industry.
Celldex Therapeutics, Inc. company overviewCelldex Therapeutics, Inc.'s most recent stock split was on February 11, 2019. It was a 1-for-15 reverse split, so shareholders received 1 share for every 15 they held.
Celldex Therapeutics, Inc. (GETTEX:TCE2) has split its stock 2 times: a 1-for-12 reverse split on March 10, 2008 and a 1-for-15 reverse split on February 11, 2019.
Celldex Therapeutics, Inc. has split its stock 2 times. This history records 2 reverse splits between March 10, 2008 and February 11, 2019.
A reverse stock split combines several shares into one and raises the price per share by the same factor, so the total value of a holding does not change. In Celldex Therapeutics, Inc.'s 1-for-15 reverse split on February 11, 2019, every 15 shares became one share. Companies often use reverse splits to lift a low share price, for example to keep meeting an exchange's minimum price requirement.
Celldex Therapeutics, Inc. has not announced a new split in our records. Its most recent split was on February 11, 2019, 7 years ago. Companies announce splits in advance, and any new GETTEX:TCE2 split will appear on this page.